Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07YHY
|
||||
| Former ID |
DIB013013
|
||||
| Drug Name |
CR-2093
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Intestine cancer [ICD10:C17-C20, C26] | Discontinued in Phase 1 | [1] | ||
| Company |
Rotta Research Lab SpA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H25ClN2O4
|
||||
| Canonical SMILES |
C(=O)(N[C@@H](C(=O)NCCC(C)(C)C)CCC(=O)O)c1cc(Cl)ccc1
|
||||
| CAS Number |
CAS 136374-73-7
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Gastrin/cholecystokinin type B receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gastric acid secretion | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001442) | ||||
| REF 2 | Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.